Treatment of Plaque Psoriasis With Interleukin-17 Inhibitors
Treatment of Plaque Psoriasis With Interleukin-17 Inhibitors
The molecular features of IL-17 made it an attractive therapeutic target and specifically as targeted therapy in plaque psoriasis. Currently, three monoclonal antibodies targeting IL-17 are in clinical development – brodalumab, ixekizumab and secukinumab.
Brodalumab is a human, anti-IL-17-receptor (anti–IL-17RA) monoclonal antibody that binds with high affinity to human interleukin-17RA. IL-17RA blockade inhibits the biologic activity of interleukins 17A, 17F, 17A/F heterodimer and 17E (IL-25). Ixekizumab is a humanized immunoglobulin G4 (IgG4) monoclonal antibody and secukinumab is a fully human IgG1κ monoclonal antibody that selectively bind and neutralize IL-17A.
Therapeutic Implications of Il-17 Inhibition
The molecular features of IL-17 made it an attractive therapeutic target and specifically as targeted therapy in plaque psoriasis. Currently, three monoclonal antibodies targeting IL-17 are in clinical development – brodalumab, ixekizumab and secukinumab.
Brodalumab is a human, anti-IL-17-receptor (anti–IL-17RA) monoclonal antibody that binds with high affinity to human interleukin-17RA. IL-17RA blockade inhibits the biologic activity of interleukins 17A, 17F, 17A/F heterodimer and 17E (IL-25). Ixekizumab is a humanized immunoglobulin G4 (IgG4) monoclonal antibody and secukinumab is a fully human IgG1κ monoclonal antibody that selectively bind and neutralize IL-17A.
Source...